Promise for Relmada Therapeutics’s antidepressant REL-1017, but more data required

[cafead]

via On 20 September, Relmada Therapeutics announced positive efficacy and safety data from a long-term, open-label, non-comparative, registrational Phase III trial (NCT04855760) for its antidepressant REL-1017 (esmethadone hydrochloride) in patients who had not previously been treated with the drug.

article source